You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. A universal eye drop adherence monitor to measure and improve adherence to ocular medications

    SBC: Universal Adherence LLC            Topic: N

    Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. The Kappa Partial Agonist PPL-103 as a Potential Cocaine Abuse Pharmacotherapy

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currentlyclinically used drug abuse medications exist for treatment of addiction to opiatesalcoholand nicotinebut not cocaineThe objective of the proposed project is to test the hypothesis that the partial kappa agonist PPLcan be effective as a pharmacotherapy for treatment of cocaine abuseBecause of chronic drug induced changes in the kappa opioid receptor systemkappa receptor directed c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Small molecule Inhibitors of steroid receptor coactivator to treat breast cancer

    SBC: Coactigon, Inc.            Topic: 102

    ABSTRACTSteroid Receptor CoactivatorSRCis a key breast cancer oncogene that is frequently overexpressed or amplified in estrogen receptorERand human epidermal growth factor receptorHERpositive breast cancersElevated expression of SRCalso has been associated with resistance to tamoxifen therapy and with poor disease outcome in HERpositive breast cancersNumerous studies have shown that experimental ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury

    SBC: Allinaire Therapeutics, LLC            Topic: NHLBI

    Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease

    SBC: Amprion, Inc.            Topic: NIA

    ABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a novel platform for rapid identification of drug targets and anti-targets

    SBC: Truvitech, LLC            Topic: NCATS

    PROJECT SUMMARY Drugs act by altering the activities of particular componentstargetswithin a cell or organismThusdrug discovery campaigns begin by identifying a targetfollowed by screening this target with compounds to identify leads that can be developed into a drugUnfortunatelyidentifying effective drug targets for a given diseaselet alone for individual patientse gin highly heterogeneous cancer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical Development of 2nd Generation HIV Maturation Inhibitors

    SBC: DFH Pharma, Inc            Topic: 400

    Project SummaryDespite advances in the development of HIV drugs there remains a need for new therapiesToxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antiviralsMaturation inhibitorsMIsrepresent one such class of HIV therapiesHIV maturation inhibitors block virus replication by disrupting the con ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. In Silico Identification of Novel GHB Receptor Ligands for SSADH Deficiency, a Disorder of GABA Metabolism

    SBC: SPERAGEN, INC.            Topic: 102

    Summary The most prevalent inherited disorder of GABA metabolismsuccinic semialdehyde dehydrogenase deficiencySSADHDpresents a non specific neurological phenotype associated with physiological accumulation of the major inhibitory neurotransmitter GABA and the GABAderivativehydroxybutyrateGHBAn absence of targeted therapy for SSADHD underlies this application s rationalePreclinical and clinical stu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government